S
Shigehiro Katayama
Researcher at Saitama Medical University
Publications - 251
Citations - 11344
Shigehiro Katayama is an academic researcher from Saitama Medical University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 49, co-authored 251 publications receiving 10637 citations.
Papers
More filters
Journal ArticleDOI
LDL Apheresis Reduces the Susceptibility of LDL to in Vitro oxidation in a Diabetic Patient With Hemodialysis Treatment
TL;DR: A LDL subfraction that was susceptible to oxidation was removed by LDL apheresis, resulting in reduction of susceptibility of LDL to in vitro oxidation remaining in plasma.
Journal ArticleDOI
Apoptosis of Endothelial Cells may be Mediated by Genes of Peroxisome Proliferator-activated Receptor γ1 (PPAR γ1) and PPARα Genes
Ikuo Inoue,Kenji Hayashi,Fumiharu Yagasaki,Koh-ichi Nakamura,Toshiyuki Matsunaga,Haiyuan Xu,Koh-ichi Inukai,Takuya Awata,Tsugikazu Komoda,Shigehiro Katayama +9 more
TL;DR: The results suggest that the apoptosis of endothelial cells may be mediated by genes of PPARgamma1 and PPARalpha, both of which are involved in apoptosis in HUVECs.
Journal ArticleDOI
Induction of autoimmune hypothyroidism and subsequent hyperthyroidism by TSH receptor antibodies following subacute thyroiditis: a case report.
Makoto Iitaka,Sachiko Kakinuma,Kayo Yamanaka,Satomi Fujimaki,Ikurou Oosuga,Seiki Wada,Shigehiro Katayama +6 more
TL;DR: This case indicates that subacute thyroiditis can induce thyroid autoimmunity, and that the character of TSH receptor antibodies (TSHRAb) in these patients can change thereby modifying their thyroid function.
Journal ArticleDOI
Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy.
Hiroyuki Iizuka,Takuya Awata,Masataka Osaki,Tamotsu Neda,Susumu Kurihara,Kiyoaki Inoue,Kouichi Inukai,Sho Kabasawa,Keisuke Mori,Shin Yoneya,Shigehiro Katayama +10 more
TL;DR: It is demonstrated that the PEDF gene, in cooperation with the VEGf gene, may contribute to the development of diabetic retinopathy (DR).
Journal ArticleDOI
Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance.
Yuichi Shinoda,Ikuo Inoue,Takanari Nakano,Makoto Seo,Masatoshi Sassa,Sei-ichi Goto,Takuya Awata,Tsugikazu Komoda,Shigehiro Katayama +8 more
TL;DR: It is shown that acarbose could improve fibrinolysis in patients with IGT, mainly by ameliorating insulinemia, and other favorable effects of acarbOSE, such as reduction in the plasma levels of oxidized low-density lipoprotein, glucose toxicity, and hyperglycemia, might also contribute, at least in part, to the beneficial effects of the drug.